Antioxidants and coronary artery disease

Current Opinion in Lipidology

Volumn 9, Issue 6, 1998, Pages 541-549

  Faggiotto, Agostino L ^a   Poli, Andrea ^a   Catapano, Alberico Luigi ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA CAROTENE; CALCIUM CHANNEL BLOCKING AGENT; ESTROGEN; FLUINDOSTATIN; MOLYBDENUM; NICOTINIC ACID; PRAVASTATIN; RETINOL; RIBOFLAVIN; SELENIUM; TRACE ELEMENT; ZINC;

CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DISEASE COURSE; FOOD ANALYSIS; HEART PROTECTION; HUMAN; ORAL DRUG ADMINISTRATION; OXIDATION; PRIORITY JOURNAL; REVIEW;

ADULT; AGED; ANTIOXIDANTS; CORONARY DISEASE; FEMALE; FOOD; HUMANS; MALE; MIDDLE AGED; MINERALS;

EID: 0032435182     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199812000-00005     Document Type: Review

References (74)

1. Buring JE, Hennekens CH. Antioxidant vitamins and cardiovascular disease. Nutr Rev 1997; 55:S53-S58.
2. Rimm EB, Stampfer MJ. The role of antioxidants in preventive cardiology. Curr Opin Cardiol 1997; 12:188-194.
3. Maxwell SRJ, Lip GYH. Free radicals and antioxidants in cardiovascular disease. Br J Clin Pharmacol 1997; 44:307-317.
4. Lonn EM, Yusuf S. Is there a role for antioxidant vitamins in the prevention of cardiovascular diseases? An update on epidemiological and clinical trials data. Can J Cardiol 1997; 13:957-965.
5. Halliwell B, Gutteridge JMC. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990; 186:1-85.
6. Fuchs D, Gruber A, Uberall F, Wachter H. Oxidative stress and apoptosis. Immunol Today 15:496.
7. Mccarty MF. Nitric oxide deficiency, leukocyte activation, and resultant ischemia are crucial to the pathogenesis of diabetic retinopathy/ neuropathy-preventive potential of antioxidants, essential fatty acids, chromium, ginkolides, and pentoxifylline. Medical Hypotheses 1998; 50:435-449.
8. Wali SO, Bahammam AS, Massaeli H, Pierce GN, Iliskovic N, Singal PK, Kryger MH. Susceptibility of LDL to oxidative stress in obstructive sleep apnea. Sleep 1998; 21:290-296.
9. Batra S, Ray G, Singh SK, Kumari S, Ravi RNM, Tandon A. Respiratory diseases in children are associated with increased serum free radical scavenging activity. Med Sci Res 1998; 26:357-359.
10. Tsopanakis C, Tsopanakis A. Stress, hormonal factors, fatigue, and anti-oxidant responses to prolonged speed driving. Pharmacol Biochem Behav 1988; 60:747-751.
11. Ursini F, Zamburlini A, Cazzolato G, Maiorino M, Bon GB, Sevanian A. • Postprandial plasma lipid hydroperoxides - a possible link between diet and atherosclerosis. Free Rad Biol Med 1998; 25:250-252. Using sophisticated technical approaches, the authors show that during the postprandial phase lipoproteins are more prone to oxidation, perhaps demonstrating a link between the postprandial phase and atherosclerosis.
12. Wei YH, Pang CY, Lee HC, Lu CY. Roles of mitochondrial DAN mutation and oxidative damage in human aging. Curr Sci 1998; 74:887-893.
13. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-809.
14. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoproteins that increase its atherogenicity. N Engl J Med 1989; 320:915-924.
15. Gaziano JM, Manson JE, Buring JE, Hennekens CH. Dietary antioxidants and cardiovascular disease. Ann NY Acad Sci 1992; 669:249-258.
16. The World Health Report conquering suffering, enriching humanity. Geneva: World Helath Organization; 1997. p. 39.
17. Acheson RM, Williams DRR. Does consumption of fruit and vegetables protect against stroke? Lancet 1983; 1:1191-1193.
18. Armstrong BK, Mann JL, Adelstein AM, Eskin F. Commodity consumption and ischemic heart disease mortality, with special reference to dietary practices. J Chronic Dis 1975; 36:673-681.
19. Gey KF, Brubacher GB, Stahelin HB. Plasma levels of antioxidant vitamins in relation to ischemic heart disease and cancer. Am J Clin Nutr 1987; 45 (suppl 5):1368-1377.
20. Gey KF, Puska P. Plasma vitamins E and A inversely correlated to mortality from ischemic heart disease in cross-cultural epidemiology. Ann NY Acad Sci 1989; 570:268-282.
21. Salonen JT, Salonen R, Seppanen K, Kantola M, Parviainen M, Alfthan G, et al. Relationship of serum selenium and antioxidants to plasma lipoproteins, platelet aggregability and prevalent ischaemic heart disease in Eastern Finnish men. Atherosclerosis 1988; 70:155-160.
22. Riemersma RA, Oliver M, Elton RA, Alfthan G, Vartiainen E, Salo M, Rubba P, et al. Plasma antioxidants and coronary heart disease: vitamins C and E, and selenium. Eur J Clin Nutr 1990; 44:143-150.
23. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. A prospective study of vitamin E consumption and risk of coronary disease in women. N Engl J Med 1993; 328:1444-1449.
24. Gaziano JM, Manson JE, Branch LG, Colditz GA, Willett WC, Buring JE. A prospective study of consumption of carotenoids in fruits and vegetables and decreased cardiovascular mortality in the elderly. Ann Epidemiol 1995; 5:255-260.
25. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328:1450-1456.
26. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology 1992; 3:194-202.
27. Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in post-menopausal women. N Engl J Med 1996; 334:1156-1162.
28. Hercberg S, Galan P, Preziosi P, Alfarez MJ, Vazquez C. The potential role of antioxidant vitamins in preventing cardiovascular disease and cancers. Nutrition 1998; 14:513-520.
29. Gaziano JM, Johnson EJ, Russell RM, Manson JE, Stampfer MJ, Ridker PM, et al. Discrimination in absorption or transport of beta-carotene isomers after oral supplementation with either all-trans or 9-cis-beta carotene. Am J Clin Nutr 1995; 61:1248-1252.
30. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330:1029-1035.
31. Lonn EM, Yusuf S. Is there a role for antioxidant vitamins in the prevention of cardiovascular diseases? An update on epidemiological and clinical trials data. Can J Cardiol 1997; 13:957-965.
32. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993; 85:1483-1492.
33. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) randomized controlled trial of vitamin E in patients with coronary disease. Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347:781-786.
34. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta-carotene and vitamin A on lung cancer incidence, total mortality, and cardiovascular mortality in smokers and asbestos-exposed workers. N Engl J Med 1996; 334:1150-1155.
35. Hercberg S, Preziosi P, Briancon S, Galan P, Triol I, Malvy D, et al. • A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population-the SUVIMAX study-design, methods, and participant characteristics. Contr Clin Trials 1998; 19:336-351. A study designed to address the issue of antioxidants and CVD nutritional doses may not prove effective.
36. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves •• endothelium-dependent vasodilatation by restoring nitric oxide activity in essential hypertension. Circulation 1998; 87:2222-2229. A very elegant study demonstrating the acute effects of water soluble vitamin C on endothelial dysfunction.
37. Tardif JC, Cote G. Lesperance J, Bourassa M, Lambert J, Doucet S, et al. •• Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. New Engl J Med 1997; 337:365-372. Probucol effectively reduces the extent of restenosis after angioplasty, but whether this is dependent solely on the antioxidant activity remains to be addressed.
38. Baldassarre D, Franceschini G, Peruzzotti G, Brusoni B, Sirtori CR. Clinical evaluation of probucol in hypercholesteremia: individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression. J Cardiovasc Pharmacol 1997; 30:784-789.
39. Yokoi H, Daida H, Kuwabara Y, Nishikawa H, Takatsu F, Tomihara H, et al. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol 1997; 30:855-862.
40. Lee YJ, Daida H, Yokoi H, Miyano H, Takaya J, Sakurai H, et al. Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty. Jpn Heart J 1996; 37:327-332.
41. Watanabe K, Sekiya M, Ikeda S, Miyagawa M, Hashida K. Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1996; 132:23-29.
42. Walldius G, Erikson U, Olsson AG, Bergstrand L, Hadell K, Johansson J, et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994; 74:875-883.
43. Anderson TJ, Meridith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332:488-493.
44. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfib• rozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998; 138:271-280. Some of the widely used hypolipidemic drugs posses antioxidant activities that may contribute to their antioxidant activity.
45. Corsini A, Maggi FM, Catapano AL. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 1995; 31:9-27.
46. Catapano AL. Calcium antagonists and atherosclerosis. Experimental evidence. Eur Heart J 1997; 18 (Suppl A):A80-A86.
47. Subbiah MT. Mechanisms of cardioprotection by estrogens. Proc Soc Exp Biol Med 1998; 217:23-29.
48. Aruoma OI, Smith C, Cecchini R, Evans PJ, Halliwell B. Free radical scavenging and inhibition of lipid peroxidation by beta-blockers and by agents that interfere with calcium metabolism. A physiologically significant process? Biochem Pharmacol 1991; 42:735-743.
49. Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992; 263:92-98.
50. Dimmitt SB, Williams PD, Croft KD, Beilin LJ. Effects of beta-blockers on the concentration and oxidability of plasma lipids. Clin Sci 1998; 94:573-578.
51. Keys A, Keys M. How to eat well and stay well. The Mediterranean way. New York: Doubleday Garden City; 1975.
52. Aviram M, Fuhrman B. Polyphenolic flavonoids inhibit macrophage-mediated oxidation of LDL and attenuate atherogenesis. Atherosclerosis 1998; 137 (suppl S):S45-S50.
53. Visioli F, Bellomo G, Galli C. Free radical-scavenging properties of olive oil polyphenols. Biochem Biophys Res Commun 1998; 247:60-64.
54. Grignaffini P, Roma P, Galli C, Catapano AL. Protection of low density lipoprotein from oxidation by 3,4-dihydroxyphenylethanol. Lancet 1994; 343:1296-1297.
55. Vinson JA, Dabbagh YA. Tea phenols-antioxidant effectiveness of teas, tea components, tea fractions and their binding with lipoproteins. Nutr Res 1998; 18:1067-1075.
56. Luo M, Kannar K, Wahlqvist ML, O'Brien RC. Inhibition of LDL oxidation by green tea extract. Lancet 1997; 349:360-361.
57. Sanbongi C, Suzuki N, Sakane T. Polyphenols in chocolate, which have antioxidant activity, modulate immune functions in humans in vitro. Cellular Immunol 1997; 177:129-136.
58. Kondo K, Hirano R, Matsumoto A, Igarashi O, Itakura H. Inhibition of LDL oxidation by cocoa. Lancet 1996; 348:1514.
59. Waterhouse AL, Shirley JR, Donovan JL. Antioxidants in chocolate. Lancet 1996; 348:834.
60. Frankel EN, Kanner J, German JB, Parks E, Kinsella JE. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet 1993; 341:454-457.
61. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary artery disease: the Zutphen Elderly Study. Lancet 1993; 342:1007-1011.
62. Leung FY. Trace elements that act as antioxidants in parenteral micronutrition. J Nutr Biochem 1998; 9:304-330.
63. Devries JHM, Hollman PCH, Meyboom S, Buysman MNCP, Zock PL, Vanstaveren WA, Katan MB. Plasma concentrations and urinary excretion of the antioxidant flavonols quercetin and kaempferol as biomarkers for dietary intake. Am J Clin Nutr 1998; 68:60-65.
64. Ahotupa M, Marniemi J, Lehtimaki T, Talvinen K, Raitakari OT, Vasankari T, et al. Baseline diene conjugation in LDL lipids as a direct measure of in vivo LDL oxidation. Clin Biochem 1998; 31:257-261.
65. Patrono C, Fitzgerald GA. Isoprostanes: potential markers of oxidant •• stress in atherothrombotic disease. Arterioscler Thromb Vase Biol 1997; 17:2309-2315. A very interesting review of the role of non-enzymatic metabolites of arachidonic acid as markers of oxidative stress.
66. Helbock HJ, Beckman KB, Shigenaga MK, Walter PB, Woodall AA, Yeo • HC, Ames BN. DNA oxidation matters: the HPLC-electrochemical detection assay of 8-oxo-deoxyguanosine and 8-oxo-guanine. Proc Natl Acad Sci USA 1998; 95:288-293. A step forward in making the determination of these products of DNA oxidation possible in the clinical laboratory.
67. Preziosi P, Galan P, Herbeth B, Valeix P, Roussel AM, Malvy D, et al. Effects of supplementation with a combination of antioxidant vitamins and trace elements, at nutritional doses, on biochemical indicators and markers of the antioxidant system in adult subjects. J Am Coll Nutr 1998; 17:244-249.
68. Chan SS, Monteiro HP, Deucher GP, Abud RL, Abuchalla D, Junqueira VBC. Functional activity of blood polymorphonuclear leukocytes as an oxidative stress biomarker in human subjects. Free Rad Biol Med 1998; 24:1411-1418.
69. Galis ZS, Asanuma K, Godin D, Meng XP. N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells - new target for antioxidant therapy. Circulation, 1998; 97:2445-2453.
70. Sen CK. Redox signaling and the emerging therapeutic potential of thiol antioxidants. Biochem Pharmacol 1998; 55;1747-1758.
71. ++ by dihydrolipoic acid prevents human low-density lipoprotein peroxidation. Free Rad Biol Med 1998; 25:287-297.
72. Nagy A, Valen G, Ek B, Sellei P, Sjoquist PO, Vaage J. Effects of a novel, low-molecular-weightinhibitor of lipid peroxidation on ischemia-reperfusion injury in isolated rat hearts and in cultured cardiomyocytes. Free Rad Biol Med 1998; 24:1462-1469.
73. Kristenson M, Zieden B, Kucinskiene Z, Elinder LS, Bergdahl B, Elwing B, et al. Antioxidant state and mortality from coronary heart disease in Lithuanian and Swedish men: concomitant cross sectional study of men aged 50. BMJ 1997; 314:629-633.
74. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990; 336:129-133.